Health & Beauty

On the 12th local time, the Global Alliance for Vaccines and Immunization announced that China National Pharmaceutical Group and Kexing Biotechnology have signed cooperation agreements with the "New Coronary Pneumonia Vaccine Implementation Plan" (COVAX) to supply vaccines. The two companies have provided vaccines to the "New Coronary Pneumonia Vaccine Implementation Plan" starting in July for the prevention and control of the epidemic in developing countries.

Vaccines will be provided in July 110 million doses will be provided by the end of October

According to the agreement, Sinopharm and Kexing Bio will provide vaccines to the "New Coronary Pneumonia Vaccine Implementation Plan" from July, and 110 million doses of vaccines will be provided by the end of October, and long-term supplies will follow for the new crown pneumonia epidemic in developing countries. Prevention and control.

According to the procurement target of the "New Coronary Pneumonia Vaccine Implementation Plan" provided by the Global Alliance for Vaccines and Immunization, by the first half of next year, up to 550 million doses of Chinese new crown vaccine will be purchased.

China has provided 500 million doses of new crown vaccine and stock solutions to the world

According to the WHO, the Chinese vaccine has been certified by the WHO for safety, effectiveness and quality. The easy storage of these two vaccines makes them very suitable for resource-poor environments. Up to now, China has provided 500 million doses of COVID-19 vaccine and stock solutions to more than 100 countries and international organizations around the world, equivalent to one-sixth of the current global output of COVID-19 vaccine.

WHO Chief Scientist: China's vaccine effectiveness is very high

Sumia Swaminathan, the chief scientist of the WHO, said that for many countries waiting for the new crown vaccine, the WHO is “very pleased that two Chinese vaccines have entered the'new crown pneumonia vaccine implementation plan' vaccine library”, and this month Vaccines can be provided from the start. At the same time, the clinical trial data of the Coxing new crown vaccine that has been carried out has shown a very high effectiveness, and the effective rate of preventing severe illness has reached 90%.